CDMO/CMO Roundup: Cambrex Creates Center of Excellence; AGC Biologics Expands
Cambrex, a contract manufacturing organization of small-molecule active pharmaceutical ingredients (APIs), and AGC Biologics, a Bothell, Washington-based contract development and manufacturing organization of biologics, have announced plans to expand contract manufacturing operations with new facility investments.
Cambrex To Establish Center of Excellence for Process Development and Clinical Supply
Cambrex plans to establish a center of excellence for API clinical supply and process development at its site in High Point, North Carolina. Cambrex will acquire its currently leased 35,000-square-foot facility, as well as an adjacent 45,000-square-foot building, which will be fitted out with kilo-scale and pilot-scale vessels, continuous reaction production, and chemistry, engineering, and analytical development laboratories.
AGC Biologics To Build New Biomanufacturing Facility in Japan
AGC Biologics plans to establish a new process development and manufacturing facility in Chiba, Japan. The new facility, which is expected to be operational in the second half of 2019, will contain single-use bioreactors at the 500- and 2,000-liter scale and will be suited for producing monoclonal antibodies, fusion proteins, and other types of therapeutic proteins.
Source: AGC Biologics